Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,022 across all filing types
Latest filing 2022-03-01 Regulatory Filings
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated March 1, 2022. It announces that BioCardia, Inc. received a No Objection Letter from Health Canada to expand a clinical trial into Canada. The document includes a press release as an exhibit but does not contain financial statements or detailed financial data. The length is 3206 characters, which is relatively short and primarily serves as an announcement of an event rather than a full report. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like earnings release or annual report.
2022-03-01 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-14 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 10, 2022. It announces that the company's independent Data Safety Monitoring Board completed a data review for an ongoing clinical trial and that a press release is attached as Exhibit 99.1. The document is relatively short (4233 characters) and primarily serves as a disclosure of a press release and regulatory update rather than containing detailed financial data or comprehensive report content. It does not contain financial statements or substantive financial analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2022-02-14 English
ROUMELL ASSET MANAGEMENT, LLC
Major Shareholding Notification
2022-02-07 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated January 31, 2022. It announces an event: the FDA granting Breakthrough Device Designation for a product. The document includes a press release as an exhibit but does not contain financial statements or detailed financial data. The length is 3247 characters, which is relatively short and consistent with an announcement rather than a full report. The content is an event disclosure rather than a financial report, management change, or other specific category. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-02-03 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 14, 2021. It reports the entry into a material definitive lease agreement and the creation of a direct financial obligation. The document includes a press release as an exhibit and references that the full lease agreement will be filed as an exhibit to the company's upcoming Annual Report on Form 10-K. The content is an announcement of a material event (lease agreement and financial obligation) rather than a full financial report or detailed management discussion. It is not an earnings release, annual report, or interim report. The Form 8-K is a regulatory filing used to announce significant corporate events. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is about 4,830 characters, which is consistent with a typical 8-K filing. Confidence is high due to the clear identification of the document as a Form 8-K and the nature of the content.
2021-12-15 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.